ATE415972T1 - Präventiver oder therapeutischer wirkstoff gegen glaukom - Google Patents

Präventiver oder therapeutischer wirkstoff gegen glaukom

Info

Publication number
ATE415972T1
ATE415972T1 AT05819681T AT05819681T ATE415972T1 AT E415972 T1 ATE415972 T1 AT E415972T1 AT 05819681 T AT05819681 T AT 05819681T AT 05819681 T AT05819681 T AT 05819681T AT E415972 T1 ATE415972 T1 AT E415972T1
Authority
AT
Austria
Prior art keywords
therapeutic agent
glaucoma
preventive
agent against
salt
Prior art date
Application number
AT05819681T
Other languages
English (en)
Inventor
Makoto Kanebako
Masatoshi Takahashi
Ken Mizuno
Shin Sugimoto
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Application granted granted Critical
Publication of ATE415972T1 publication Critical patent/ATE415972T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05819681T 2004-12-23 2005-12-22 Präventiver oder therapeutischer wirkstoff gegen glaukom ATE415972T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63811804P 2004-12-23 2004-12-23

Publications (1)

Publication Number Publication Date
ATE415972T1 true ATE415972T1 (de) 2008-12-15

Family

ID=36601805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05819681T ATE415972T1 (de) 2004-12-23 2005-12-22 Präventiver oder therapeutischer wirkstoff gegen glaukom

Country Status (24)

Country Link
EP (1) EP1818059B1 (de)
JP (1) JP4099201B2 (de)
KR (1) KR101286813B1 (de)
CN (1) CN101087613B (de)
AT (1) ATE415972T1 (de)
AU (1) AU2005320085B2 (de)
BR (1) BRPI0519007A2 (de)
CA (1) CA2585372A1 (de)
CY (1) CY1108651T1 (de)
DE (1) DE602005011476D1 (de)
DK (1) DK1818059T3 (de)
EA (1) EA011085B1 (de)
ES (1) ES2317338T3 (de)
HK (1) HK1113312A1 (de)
MX (1) MX2007007614A (de)
MY (1) MY138811A (de)
NO (1) NO20072187L (de)
NZ (1) NZ555137A (de)
PL (1) PL1818059T3 (de)
PT (1) PT1818059E (de)
SI (1) SI1818059T1 (de)
TW (1) TWI367098B (de)
WO (1) WO2006068208A1 (de)
ZA (1) ZA200704874B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007879A1 (ja) * 2005-07-14 2007-01-18 Sharp Kabushiki Kaisha 表示素子、及びこれを用いた電気機器
CA2731271A1 (en) 2008-07-25 2010-01-28 Asahi Kasei Pharma Corporation Stable aqueous solution composition containing sulfonamide compound
ES2684351T3 (es) * 2011-02-04 2018-10-02 Kowa Co., Ltd. Terapia farmacológica para prevenir o tratar glaucoma
EA026904B1 (ru) * 2012-11-23 2017-05-31 Игорь Михайлович Юхт Способ количественного определения полигексаметиленбигуанидина (пгмб) гидрохлорида в составах для приготовления жидких лекарственных средств для лечения заболеваний глаз и носа (2 варианта)
EP3626245B1 (de) * 2013-04-24 2021-05-05 Kyushu University, National University Corporation Therapeutikum für erkrankungen des augenhintergrunds
SG11201702202UA (en) * 2014-09-25 2017-04-27 Kowa Co Aqueous composition
TWI686198B (zh) * 2014-09-25 2020-03-01 日商興和股份有限公司 醫藥品
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
CA2970263A1 (en) 2014-12-12 2016-06-16 Kowa Company, Ltd. Novel aqueous composition
KR20160108121A (ko) 2015-03-06 2016-09-19 코와 가부시키가이샤 수성 조성물
JP2018118905A (ja) * 2015-04-27 2018-08-02 恵 本庄 白内障術後合併症の予防治療剤
CN106310285A (zh) * 2015-06-15 2017-01-11 江苏吉贝尔药业股份有限公司 一种新的盐酸利舒地尔滴眼液及其制备方法
JP6886322B2 (ja) * 2016-03-25 2021-06-16 興和株式会社 眼科用組成物
CN107164328A (zh) * 2017-06-30 2017-09-15 太仓卡斯特姆新材料有限公司 一种高稳定性mcf‑7乳腺癌细胞的复苏方法
ES2972934T3 (es) 2017-12-21 2024-06-17 Santen Pharmaceutical Co Ltd Combinación de sepetaprost y ripasudil para su uso en la profilaxis o tratamiento del glaucoma o hipertensión ocular
JP2020193174A (ja) * 2019-05-29 2020-12-03 興和株式会社 水性組成物
US11918581B2 (en) 2021-01-11 2024-03-05 Incyte Corporation Combination therapy comprising JAK pathway inhibitor and rock inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9401108D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
DE19512639A1 (de) * 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitrile und -fluoride
CN1155383C (zh) * 1995-12-21 2004-06-30 阿尔康实验室公司 某些异喹啉磺酰基化合物治疗青光眼及眼局部缺血的用途
WO1999054306A1 (fr) * 1997-03-10 1999-10-28 Hiroyoshi Hidaka Derives isoquinolinesulfonamide et medicaments integrant ces derives comme principe actif
JPH10310576A (ja) * 1997-03-10 1998-11-24 Hiroyoshi Hidaka イソキノリンスルフォンアミド誘導体及びこれを有効成分とする医薬
SK285991B6 (sk) * 1997-04-25 2008-01-07 Pfizer Inc. Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
FR2777189B1 (fr) 1998-04-09 2001-04-06 Chauvin Lab Sa Composition ophtalmique comprenant un beta-bloquant
JP4212149B2 (ja) * 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
JP3720264B2 (ja) 1998-08-17 2005-11-24 千寿製薬株式会社 緑内障予防・治療剤
EP1514867A3 (de) * 1998-10-22 2005-03-23 NeuroSearch A/S Substituierte Phenylderivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
AU2005320085A1 (en) 2006-06-29
JP4099201B2 (ja) 2008-06-11
EP1818059B1 (de) 2008-12-03
CN101087613B (zh) 2010-08-18
EA200701134A1 (ru) 2007-10-26
HK1113312A1 (en) 2008-10-03
EA011085B1 (ru) 2008-12-30
MY138811A (en) 2009-07-31
EP1818059A1 (de) 2007-08-15
AU2005320085B2 (en) 2010-07-29
CA2585372A1 (en) 2006-06-29
MX2007007614A (es) 2007-08-15
PT1818059E (pt) 2008-12-31
NZ555137A (en) 2009-10-30
SI1818059T1 (sl) 2009-04-30
BRPI0519007A2 (pt) 2008-12-23
PL1818059T3 (pl) 2009-05-29
KR20070090897A (ko) 2007-09-06
TW200628160A (en) 2006-08-16
DE602005011476D1 (de) 2009-01-15
CN101087613A (zh) 2007-12-12
TWI367098B (en) 2012-07-01
JPWO2006068208A1 (ja) 2008-06-12
DK1818059T3 (da) 2009-03-16
ZA200704874B (en) 2008-08-27
WO2006068208A1 (ja) 2006-06-29
ES2317338T3 (es) 2009-04-16
CY1108651T1 (el) 2014-04-09
NO20072187L (no) 2007-07-13
EP1818059A4 (de) 2007-12-26
KR101286813B1 (ko) 2013-07-17

Similar Documents

Publication Publication Date Title
ATE415972T1 (de) Präventiver oder therapeutischer wirkstoff gegen glaukom
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2007076367A3 (en) Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma
IL160420A0 (en) Treating or preventing diabetes with cannabidiol
ATE480240T1 (de) Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukom
EP1592435A4 (de) Augenformulierung zur vorbeugung und behandlung von augenleiden
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2006066103A3 (en) Ophthalmic implant for treatment of glaucoma
WO2008070726A3 (en) Treatment for dry eye
HK1102913A1 (en) Statins for the treatment of ocular hypertension and glaucoma
NO20060114L (no) Naftylenderivater som cytokrom P450-inhibitorer
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
WO2007126364A8 (en) Use of antisecretory factors for treating intraocular hypertension
MX2008015976A (es) Tratamiento topico para enfermedades de superficie ocular.
WO2004066979A3 (en) Sustained release device and method for ocular delivery of adrenergic agents
EP1752158A4 (de) Pacap und sein derivat enthaltender korneaneuritogenese-promoter
WO2007045930A3 (en) Modulation of trpv expression levels
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
EP1482922A4 (de) Mittel für die corneale oder intrastromale verabreichung zur behandlung oder prävention von erkrankungen des auges
UA94938C2 (ru) Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты)
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
TW200806284A (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
WO2004087051A3 (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1818059

Country of ref document: EP